Introduction
============

Hepatocellular carcinoma (HCC) is a major malignant disease worldwide and poses a global concern. However, previously the role of radiotherapy (RT) in HCC had been ignored because of the low tolerance dose of radiation for the whole liver, which was not satisfactory for tumor control.[@b1-ott-9-3807] With the advanced techniques of RT, it has been possible to deliver a higher dose of radiation to part of the liver accurately without a significant dose increase in the other adjacent critical structures, especially the normal liver parenchyma.[@b2-ott-9-3807] Now, much progress has been made in improving the therapeutic index of RT against HCC. According to the National Comprehensive Cancer Network (NCCN) practice guidelines of 2015 (revised), all tumors of HCC irrespective of the location may be amenable to external-beam RT (NCCN guidelines Version 1.2015). That was the first time, RT was included in NCCN as one of the comprehensive treatments for HCC.

Some studies have reported that increased radiation doses generate increased local control and survival independent of the tumor size.[@b2-ott-9-3807],[@b3-ott-9-3807] However, a high radiation dose to the liver is accompanied by acute and late hepatic toxicity, and radiation-induced liver disease (RILD) has been one of the most important treatment-related complications.[@b1-ott-9-3807] A few dosimetric analyses have reported the interrelation between dose/volume parameters and the risk of RILD, and the results have been helpful in the radiation treatment plans intended to reduce RILD.[@b4-ott-9-3807]--[@b7-ott-9-3807] Such findings encouraged additional endeavors to increase the focal liver dose for patients with unresectable intrahepatic tumors.[@b3-ott-9-3807] The issue of how to maximize therapeutic effects by increasing the radiation dose while simultaneously sparing the adjacent normal liver is a major subject of ongoing investigations.

Modern radiation oncologists have more choice available to them than ever before for highly precise delivery of partial liver irradiation, such as three-dimensional conformal radiotherapy (3DCRT), intensity-modulated RT (IMRT), and helical tomotherapy (HT). Variations in the irradiation techniques lead to different dose distributions. HT had been shown to possess equivalent or superior capability to 3DCRT and IMRT for some malignancies, including nasopharyngeal carcinoma and endometrial cancer.[@b8-ott-9-3807],[@b9-ott-9-3807] But the effectiveness of HT in sparing normal liver and the potential of increasing the prescription dose for localized intrahepatic cancers specifically is unclear.

In this study, the difference between the treatment schemes (3DCRT, IMRT, and HT) in sparing normal liver was compared in the treatment of HCC. Furthermore, the study of dose increase was performed with higher tumor control and acceptable risk of complications.

Patients and methods
====================

Patient selection
-----------------

The hospital records, imaging studies, and laboratory results of patients with HCC who received RT at our hospital from January 2013 to April 2015 were retrospectively reviewed. The inclusion criteria were as follows: 1) the diagnosis of HCC made either histologically or by elevated serum α-fetoprotein levels (\>400 ng/mL) with typical radio-logic findings; 2) HCC with single lesion confined to the liver; 3) good general condition with Eastern Cooperative Oncology Group performance status of 2 or less and a Child--Pugh classification of A or B; and 4) whether the patients experienced transarterial chemoembolization. The study protocol was approved by the Medical Ethics Committee of the Shandong Cancer Hospital and Institute. All participants provided written informed consent.

Immobilization, simulation, and target delineation
--------------------------------------------------

The patients were immobilized supinely with their arms above their heads using vacuum casts. All patients used respiratory control and abdominal compression to reduce the uncertainty bias caused by respiratory movements and organ motion. Two series of axial CT (computerized tomography) images, with contrast enhancement, with 3 mm slick thickness including whole liver and kidneys, were acquired for each patient. The simulation CT image sets were then transferred to a Varian treatment planning system for 3DCRT and IMRT planning. After delineating all of the essential targets and organs at risk (OARs), CT datasets with structures were transferred to the tomotherapy planning system.

The gross tumor volume was defined as the primary tumor visualized in contrast-enhanced CT images. Subsequently, a 5 mm margin was added to create the clinical target volume. The planning target volume (PTV) was generated as the clinical target volume with a 5 mm radial expansion and a 10 mm craniocaudal expansion, taking into account patient set-up errors and respiratory liver motion. OARs including the total liver, nontarget normal liver (NTNL), stomach, kidneys, and spinal cord were also delineated for evaluation of the irradiation dose. NTNL volume was taken as the total liver volume minus PTV. All the structures were outlined by an experienced radiation oncologist.

Treatment planning
------------------

The 3DCRT and IMRT plans were all designed on a Varian Eclipse Version 8.6.23 treatment planning system. HT plans were performed with a TomoTherapy^®^ Planning Station (TomoH™ Version 2.0.1). The calculations of 3DCRT and IMRT planning systems were performed with the Anisotropic Analytical Algorithm (Version 8.9.17) and a grid of 2.5 mm. HT used a superposition convolution algorithm, and the calculations were done on a fine grid with a resolution of 1.875×1.875 mm^2^. All plans were designed to achieve optimal NTNL sparing as much as possible while covering at least 95% of the PTV. Photon beams of 6 MV or 15 MV were used for 3DCRT and IMRT plans, and 6 MV beams for HT plans. For 3DCRT and IMRT plans, proper number and beam orientation for the fields were chosen carefully to achieve the target goals and reduce the entering beam path in the normal liver according to the relationship between the PTVs and OARs. The beam setups of each individual patient in this study were designed to find the best achievable designs with NTNL sparing. The beams were directed toward the tumor along paths through the smallest liver volume to minimize the amount of normal liver exposed to even low doses of radiation. The number of fields of 3DCRT varied from 4 to 7, and that of IMRT was 5 or 7 divided unequally. A dose rate of 300 MU/min was used for all cases. For HT plans, the iterations were based on both the target goals and dose constraints of critical structures, with the NTNL constraints as the priority. In our study, the field width and the pitch used for the HT planning optimization were 2.51 cm and 0.285, respectively. The modulation factor was set to be 2.5 before optimization and adjusted during the optimization to find the optimal value. NTNLs were directionally blocked according to the relationship between PTVs and NTNLs in all HT plans. Directional blocking was used to limit the beam angles.

Evaluation of treatment plans
-----------------------------

The starting prescribed doses were 50 Gy/25 fractions while meeting the OARs constraints. Then the prescription dose was increased using HT or IMRT independently at nominal 4% increments until either the plans reached 70 Gy or any normal tissue reached the dose limit according to quantitative analysis of normal tissue effects in the clinic (QUANTEC) criteria[@b10-ott-9-3807] and other reports.[@b7-ott-9-3807],[@b11-ott-9-3807],[@b12-ott-9-3807] The specific dose constraints were as follows: *D*~mean~ (mean dose) of normal liver ≤23 Gy; *D*~mean~ of liver ≤28 Gy, *V*~30~ of liver \<50%; maximum dose of stomach ≤54 Gy; at least one side of kidney ≤23 Gy (mean dose); and maximum dose of spinal cord ≤47 Gy. The PTV doses were prescribed to cover \>95% of the PTV with no greater than 110% of the maximum point dose. To avoid any biases in the optimization and evaluation processes, normalization was set to the PTV mean dose. Having achieved these objectives, the plans were generated by the same physicist and approved by the same oncologist. For PTVs, the conformal index (CI) is defined as $\frac{\text{TV}_{\text{PV}}/V_{\text{PTV}}}{V_{\text{TV}}/\text{TV}_{\text{PV}}}$, where *V*~PTV~ is the volume of PTV, *V*~TV~ is the volume enclosed by the prescription dose line, and TV~PV~ is the volume of PTV within the prescribed isodose volume.[@b13-ott-9-3807] The homogeneity index (HI) is defined as $\frac{D_{5\%}}{D_{95\%}}$, where *D*~5%~ and *D*~95%~ are the minimum doses delivered to 5% and 95%, respectively, of the PTV.[@b12-ott-9-3807] The value of CI ranged from 0 to 1, and HI varied from infinity to 1. The closer the value is to 1, the better is the result. For OARs, the parameters included *D*~mean~, the maximum dose (*D*~max~), and a set of appropriate *V*~n~ (the percentage of organ volume receiving ≥n Gy). We evaluated each treatment plan using a dose--volume histogram and visually inspecting the isodose curves. Delivery time was recorded to assess the efficiency of treatment delivery.

Statistical analysis
--------------------

The mean values (standard deviation) of the dosimetric data for the patients between the three plans were analyzed using the Friedman test. When a significant difference was found, the difference between two plans for each effect was further examined by the Wilcoxon signed-rank test. All *P*-values were two-tailed, and a value of 0.05 was considered statistically significant. All statistical analyses were performed using the SPSS Version 17.0 software (IBM Corporation, Armonk, NY).

Results
=======

Patient and tumor characteristics
---------------------------------

Sixteen patients with a single tumor confined to the liver were recruited for the study, and their median age was 57 years (range, 37--66 years). The ratio of males-to-females was 7:1. Ten and six patients were Child--Pugh class A and class B, respectively. All patients had received other treatments before RT. Fifteen patients were treated with transarterial chemoembolization (median number of procedures, 3; range, 1--6), and one patient was treated with radiofrequency ablation and transarterial chemoembolization. All tumors were confined to the liver without lymph node metastasis. The mean value of the volume and equivalent sphere diameter of the gross tumors were 348.57±206.11 (range, 147.20--698.30 cm^3^) and 10.64±2.54 (range, 6.95--15.72 cm^3^), respectively. The mean value of normal liver volume was 1,208.61±415.73 cm^3^ (range, 965.34--1,696.21 cm^3^). [Figure 1](#f1-ott-9-3807){ref-type="fig"} shows the isodose distributions in one representative patient obtained with 3DCRT, IMRT, and HT at the prescription dose of 50 Gy/25 fractions. [Figure 2](#f2-ott-9-3807){ref-type="fig"} shows the dose--volume histograms for PTV and NTNL between the three plans for the patient corresponding to [Figure 1](#f1-ott-9-3807){ref-type="fig"}.

PTV analysis and delivery time
------------------------------

[Table 1](#t1-ott-9-3807){ref-type="table"} shows the differences between the three techniques with regard to the dosimetric parameters of PTVs and treatment times for a prescription dose of 50 Gy. [Figure 3](#f3-ott-9-3807){ref-type="fig"} is a column chart of CI and HI for PTVs with the three modalities for all patients.

OARs sparing
------------

[Table 2](#t2-ott-9-3807){ref-type="table"} summarizes the dose statistics of the specified OARs with prescribed dose of 50 Gy. For mean value of *V*~50%~ (fraction of normal liver treated to at least 50% of the prescription dose) of normal liver, there was a significant difference: 3DCRT \> IMRT \> HT (*P*\<0.001). HT had lower *D*~mean~ and *V*~20~ of liver compared with 3DCRT (*P*=0.005, *P*=0.005) or IMRT (*P*=0.508, *P*=0.007). For *D*~mean~ of NTNL and *V*~30~ of liver, 3DCRT was higher than IMRT (*P*=0.005, *P*=0.005) or HT (*P*=0.005, *P*=0.005).

Dose-escalation potential of HT and IMRT
----------------------------------------

We increased the prescribed dose for all patients using HT and IMRT independently in nominal 4% increments from the 50 Gy/25 fractions until either the plans reached 70 Gy/35 fractions or any normal tissue reached the dose limits as previously described. Seven patients in IMRT (43.75%) and nine patients in HT (56.25%) for whom the isodose could reach 70 Gy met the dose limit of the OARs. The increase in dose was stopped by the limit of adjacent stomach or the NTNL. For *D*~mean~ of NTNL and *V*~30~ of liver, HT (15.05±0.48 Gy and 20.32±4.00 Gy, respectively) was lower than IMRT (16.17±0.89 Gy and 26.32±3.38 Gy, respectively) (*P*=0.043, *P*=0.043). For *D*~mean~ and *V*~20~ of the liver, no difference was observed between the two techniques.

Discussion
==========

Historically, RT has not played an important role in the treatment of HCC primarily due to the relatively high radiosensitivity of the liver and the risk of RILD.[@b1-ott-9-3807],[@b14-ott-9-3807] Several dosimetric analyses for quantifying the risk of RILD have been reported. In the study by Cheng et al, the mean dose to normal liver of patients with RILD was significantly higher than those without (25.04 Gy vs 19.65 Gy, *P*=0.02), and it was the most important determinant for RILD.[@b5-ott-9-3807] The University of Michigan Medical Center showed that the mean dose to normal liver associated with a 5% risk of classic RILD was 28 Gy for primary liver tumor.[@b7-ott-9-3807] Additionally, Cheng et al[@b4-ott-9-3807] suggested that *V*~30~,42% could avoid RILD, and Kim et al[@b6-ott-9-3807] reported that *V*~30~ was a significant parameter in patients treated with conventional fractionated RT. Liang et al showed that *V*~20~ was an important parameter in patients treated with hypofractionated RT (4--6 Gy/fraction).[@b15-ott-9-3807] In the current study, the value of the mean dose of NTNL of HT was lower than for IMRT (*P*=0.047) or 3DCRT (*P*=0.005). The mean dose and *V*~30~ of liver for 3DCRT was higher than for IMRT (*P*=0.005, *P*=0.005) or HT (*P*=0.005, *P*=0.005). There was significantly lower *V*~20~ of liver for HT compared with 3DCRT (*P*=0.005) or IMRT (*P*=0.007). Theoretically, based on the correlation between these dosimetric parameters and RILD, the advantage of liver sparing of HT over 3DCRT and IMRT is clear. In other words, HT could be considered as a superior choice for HCC patients in terms of normal liver sparing compared with 3DCRT or IMRT.

Evidence of a dose--response relationship has been shown. A higher prescribed dose showed a higher survival rate. For example, Dawson et al reported that patients treated with \>70 Gy had improved in-field local control than those who received \<70 Gy (median time to in-RT field progression, 22 months vs 9 months; *P*\<0.05).[@b3-ott-9-3807] The goal of RT for HCC is to maximize therapeutic effects by increasing the radiation dose while sparing the adjacent normal organs. *V*~50%~ of normal liver had been used as the indicator for prescribing the different dose levels. Based on the University of Michigan guideline,[@b16-ott-9-3807] *V*~50%~ of normal liver is divided into three intervals: if the percentage of nontumor liver volume receiving 50% of the isocenter dose was \<33%, the total dose was increased to 66--72.6 Gy; if the percentage was 33%--66%, the dose was 48--52.8 Gy; if the percentage was \>66%, the total dose was 36 Gy. In our study, the mean values of *V*~50%~ of normal liver were 26.06%±11.28% for 3DCRT, 18.67%±8.96% for IMRT, and 15.05%±8.80% for HT. In accordance with the Michigan University guideline, there were nine patients in 3DCRT, eleven patients in IMRT, and 13 patients in HT who could receive the 66--72.6 Gy prescribed dose level, as shown in [Table 3](#t3-ott-9-3807){ref-type="table"}. This indicated that HT could allow more patients to receive a higher prescribed dose level than IMRT or 3DCRT. These data are consistent with the results of our study. Consequently, a higher prescribed dose can be given when HT is selected. In addition, from our dosimetric data, we could see that the advantage of liver sparing of HT compared with IMRT remains at the higher dose level.

To simplify plan intercomparisons, all our HT plans were assigned with the same values of jaw width (2.5 cm) and pitch (0.287). These parameters were chosen based on a combination of recommendations from other tomotherapy users and our own institutional experience. Moldovan et al reported that these parameter differences may not be radiobiologically meaningful based on the calculations of tumor control probabilities and normal tissue complication probabilities.[@b17-ott-9-3807] In the present study, we protected the NTNL with a directional blocking technique that is unique for HT. Directional blocking allows a beam to pass through a given structure only after passing through the PTV such that the structure receives the exit dose but not the entry dose.[@b18-ott-9-3807] In addition, HT shows superior dose gradient and distribution because the dose was delivered rotationally with higher intensity modulation.[@b19-ott-9-3807] With these advantages, HT could achieve better liver sparing in patients with HCC, as shown in [Figure 1](#f1-ott-9-3807){ref-type="fig"}. For irregular-shaped targets, the uniformity of dose distribution and sparing of normal liver are limited by 3DCRT. Our results show that the HI of 3DCRT was higher than that of IMRT (*P*\<0.001) or HT (*P*\<0.001), and the HI of HT was lower than that of IMRT though there was no statistical significance. Because of its 360° beam arrangement, HT planning can provide better dose distribution than IMRT or 3DCRT.[@b20-ott-9-3807] These indicate that HT can achieve greater dose heterogeneity to meet the more complicated tumor shapes. This advantage is more obvious in RT with complex targets; Han et al had shown improvements in homogeneity with HT in intracranial situations with irregular-shaped targets.[@b19-ott-9-3807] Our results are, however, at variance with those of a previous study. Song et al reported that HT could reduce the probability of radiation-induced hepatic toxicity compared to fixed-beam IMRT. However, they suggested the parameter *V*~15~ of the normal liver for predicting the probability of radiation-induced hepatic toxicity.[@b21-ott-9-3807] Not only the parameters they suggested but also the definitions of damage were different from ours. Hsieh et al[@b22-ott-9-3807] reported that HT has better potential than coplanar IMRT for HCC patients with portal vein thrombosis. They showed the superiority of HT based on the lower of *V*~30~ in the liver (21% in coplanar IMRT, 17% in tomotherapy), and the data are consistent with the results of our study.

There are some limitations with regard to our results. Any intrinsic difference in the dose calculation algorithms performed by two different treatment planning systems might produce different results. Moreover, only 16 patients were enrolled in our dosimetric analysis, which is a small number for statistical analysis. To reduce the motion of liver in RT, we used respiratory control and abdominal compression. Furthermore, we could have performed four-dimensional computed tomography using an external respiratory signal to acquire different phases of CT images for these patients to evaluate the motion of liver.[@b23-ott-9-3807]

Conclusion
==========

Compared with 3DCRT and IMRT, HT provides significantly better liver sparing considering the lower *V*~20~, *V*~30~, or the mean dose of liver in terms of the risk of RILD for HCC. Moreover, HT is an advantageous technique for increasing the prescribed dose so that it can allow more patients to receive a higher prescribed dose with higher tumor control and acceptable risk of complications in the RT of HCC.
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![Comparison of isodose distribution of PTV and OARs in (**A**) 3DCRT, (**B**) IMRT, and (**C**) HT, for one representative case with a prescription dose of 50 Gy.\
**Note:** HT achieves better conformality and normal liver sparing compared with 3DCRT or IMRT.\
**Abbreviations:** PTV, planning target volume; OARs, organs at risk; 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; HT, helical tomotherapy.](ott-9-3807Fig1){#f1-ott-9-3807}

![Comparison of the DVHs of PTVs and livers between 3DCRT, IMRT, and HT with a prescription dose of 50 Gy.\
**Notes:** The left figure (**A**) shows DVHs of PTV. These three techniques produced similar homogeneity of the PTV. The right figure (**B**) shows DVHs of the liver. HT obtained higher low-dose distribution and the lower *V*~20~ and *V*~30~ compared to 3DCRT or IMRT.\
**Abbreviations:** DVH, dose--volume histogram; PTV, planning target volume; 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; HT, helical tomotherapy.](ott-9-3807Fig2){#f2-ott-9-3807}

![Column chart of conformal index (CI) and homogeneity index (HI) for PTVs with three modalities for all patients.\
**Notes:** The left figure (**A**) shows the column chart of CI. The CI of 3DCRT is lower than that of IMRT or HT. The right figure (**B**) shows the column chart of HI. The HI of 3DCRT is higher than that of IMRT or HT.\
**Abbreviations:** PTV, planning target volume; 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; HT, helical tomotherapy.](ott-9-3807Fig3){#f3-ott-9-3807}

###### 

Summary of the dosimetric results for PTVs and delivery time with a prescribed dose of 50 Gy/25 fractions

  PTV              3DCRT (mean ± SD)   IMRT (mean ± SD)   HT (mean ± SD)   *P*-value                       
  ---------------- ------------------- ------------------ ---------------- ----------- --------- --------- -------
  *V*~95%~ (%)     99.90±0.23          99.96±0.53         99.33±0.54       0.177       --        --        --
  *V*~100%~ (%)    80.73±1.03          79.20±3.42         78.34±1.21       0.223       --        --        --
  CI               0.74±0.04           0.81±0.05          0.82±0.04        \<0.001     \<0.001   \<0.001   0.959
  HI               1.11±0.02           1.08±0.03          1.06±0.01        \<0.001     \<0.001   \<0.001   0.286
  Time (minutes)   1.27±0.09           3.77±1.12          5.56±1.37        \<0.001     0.005     0.005     0.013

**Notes:** *V~x~*~%~, the volume receiving ≥*x*% of the prescribed dose. "--" indicates overall *P*-value among three techniques \>0.05 and that there is no further comparison.

**Abbreviations:** PTV, planning target volume; 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; HT, helical tomotherapy; CI, conformal index; HI, homogeneity index; SD, standard deviation.

###### 

Comparison of dosimetric parameters of normal organs at risk with a prescribed dose of 50 Gy/25 fractions

  Structure                   3DCRT (mean ± SD)   IMRT (mean ± SD)   HT (mean ± SD)   *P*-value                   
  --------------------------- ------------------- ------------------ ---------------- ----------- ------- ------- -------
  NTNL *V*~50%~ (%)           26.06±11.28         18.67±8.96         15.05±8.80       \<0.001     0.005   0.005   0.007
  Liver *D*~mean~ (Gy)        21.49±6.33          18.99±5.80         18.06±5.45       \<0.001     0.005   0.005   0.508
  NTNL *D*~mean~ (Gy)         15.57±5.04          12.48±3.97         11.21±3.69       \<0.001     0.005   0.005   0.047
  Liver *V*~5~ (%)            72.16±9.55          66.22±13.01        68.27±11.86      0.014       0.005   0.285   0.445
  Liver *V*~10~ (%)           57.39±12.88         52.62±12.71        50.79±13.78      0.150       --      --      --
  Liver *V*~20~ (%)           40.37±17.91         37.07±13.67        31.33±13.75      \<0.001     0.139   0.005   0.007
  Liver *V*~30~ (%)           31.09±15.76         25.36±14.51        23.18±12.81      \<0.001     0.005   0.005   0.203
  Stomach *D*~mean~ (Gy)      14.24±11.83         12.31±10.59        15.14±12.12      0.122       --      --      --
  Lt kidney *D*~mean~ (Gy)    0.64±0.58           0.67±0.67          1.37±1.46        0.002       0.610   0.005   0.007
  Rt kidney *D*~mean~ (Gy)    1.54±2.42           1.45±2.63          2.33±3.05        \<0.001     0.074   0.007   0.005
  Spinal cord *D*~max~ (Gy)   20.51±11.03         14.60±14.21        26.94±9.18       0.082       --      --      --

**Notes:** *V*~50%~, fraction of normal liver treated to at least 50% of the isocenter dose; *V*~n~, the percentage of organ volume receiving ≥n Gy; *D*~mean~, the mean dose for organ; *D*~max~, the maximum dose for organ. "--" indicates overall *P*-value among three techniques \>0.05 and that there is no further comparison.

**Abbreviations:** 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; HT, helical tomotherapy; NTNL, nontarget normal liver; Lt, left; Rt, right; SD, standard deviation.

###### 

Liver tumor radiation dose prescription guideline by *V*~50%~ for the patients using different radiotherapy modalities

  *V*~50%~   Total dose (Gy)                 3DCRT patients (n)   IMRT patients(n)   HT patients (n)
  ---------- ------------------------------- -------------------- ------------------ -----------------
  \<33       Range: 66--72.6 (focal liver)   9                    11                 13
  33--66     Range: 48--52.8 (focal liver)   7                    5                  3
  \>66       Mean: 36 (whole liver)          0                    0                  0

**Note:** *V*~50%~, fraction of normal liver treated to at least 50% of the isocenter dose.

**Abbreviations:** 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiation therapy; HT, helical tomotherapy.
